[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602377":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":45,"responsibleParty":68,"collaborators":72,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":25,"enrollmentInfo":85,"targetDuration":25,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Stony Brook University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"A: Ipsilateral axillary node-negative breast cancer","EXPERIMENTAL","Patients with ipsilateral axillary lymph node-negative disease, regardless of metastatic status (Stages T1-4 N0 M0-1)",[13],"Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor",{"label":15,"type":10,"description":16,"interventionNames":17},"B: Ipsilateral axillary node-positive breast cancer","Patients with ipsilateral axillary node-positive disease, regardless of metastatic status (Stages T1-4 N1-2 M0-1)",[18],"Radiation: Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor","Radiation with 26Gy to the whole breast and 40Gy simultaneous integrated boost to gross disease in the breast, in five fractions",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Whole breast radiation with simultaneous integrated boost (WB-SIB) to primary breast tumor and ipsilateral axillary lymph nodes","Radiation with 26Gy to the whole breast and regional nodes with a 40Gy simultaneous integrated boost to gross disease in breast and ipsilateral axillary nodal areas, in five fractions",[15],[31],{"name":32,"affiliation":33,"role":34},"Alexander Stessin, MD PhD","Stony Brook University Hospital","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Caterina Stony Brook Cancer Center Clinical Trials","CONTACT","631-728-7425","cancerclinicaltrials@sronybrookmedicine.edu",{"name":42,"role":38,"phone":43,"phoneExt":25,"email":44},"Caterina Vacchi-Suzzi, PhD","6312162993","caterina.vacchi-suzzi@stonybrookmedicine.edu",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Stony Brook University Cancer Center","RECRUITING","Stony Brook","New York","11794","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-73.14094,40.92565,{"lat":58,"lon":57},[61,65,67],{"name":62,"role":38,"phone":63,"phoneExt":25,"email":64},"Cancer Clinical Trials Office","(631)-728-7425","CancerClinicalTrials@stonybrookmedicine.edu",{"name":25,"role":38,"phone":25,"phoneExt":25,"email":66},"cancerclinicaltrials@stonybrookmedicine.edu",{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"type":69,"investigatorFullName":70,"investigatorTitle":71,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Alexander Stessin","Professor, Department of Radiation Oncology",[73],{"name":74,"class":6},"Northwell Health","100602377","definitive-radiation-therapy-for-inoperable-breast-cancer-100602377",false,"NCT07122713","Definitive Radiation Therapy for Inoperable Breast Cancer","Multi-institutional Prospective Pilot Study of Definitive Breast Radiation Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery","DEFINE","Inclusion Criteria:\n\n* Biopsy proven invasive carcinoma of the breast, either lobular, ductal and\u002For no special type\n* T1-T4, N0-2, M0-1 invasive breast carcinoma by radiological or clinical criteria\n* Cancer is deemed unresectable, or the patient is a poor surgical candidate as determined following evaluation by a surgeon, or patient declines surgery.\n* Life expectancy \\> 6 months\n* Negative pregnancy test at the time of start of treatment in any female of reproductive age\n\nExclusion Criteria:\n\n* Concurrent systemic therapy (except for endocrine therapy, HER2-targeted therapy, or immunotherapy which are permitted)\n* Prior radiation to ipsilateral breast or regional nodes\n* Inability to receive study treatment planning and treatment secondary to body habitus","FEMALE","18 Years",{"count":86,"type":87},30,"ESTIMATED","INTERVENTIONAL",[90],"NA","The purpose of this study is to find out if adding radiation therapy to routine medications for breast cancer helps in reducing and preventing the cancer from getting worse. Patients with a locally advanced breast cancer who cannot, or do not want to, undergo surgery are eligible to participate. Participation in this study does not prevent you from undergoing surgery in the future.",[93,94],"Breast Cancer","Breast Adenocarcinoma",[96,97,98,99,100,101,102,103],"inoperable breast cancer","radiation therapy","breast radiation","novel treatment","new treatment breast","cyberknife","non-invasive","stereotactic radiation","2025-12-15",{"date":106,"type":107},"2025-12-17","ACTUAL",{"date":109,"type":107},"2025-12-08",{"date":111,"type":87},"2033-12-30",{"name":70,"class":6},1]